- Home
- OPAD vs CVKD Comparison
OPAD vs CVKD Comparison
Compare OPAD & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPAD
- CVKD
- Stock Information
- Founded
- OPAD 2015
- CVKD 2022
- Country
- OPAD United States
- CVKD United States
- Employees
- OPAD N/A
- CVKD N/A
- Industry
- OPAD Real Estate
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- OPAD Finance
- CVKD Health Care
- Exchange
- OPAD Nasdaq
- CVKD Nasdaq
- Market Cap
- OPAD 28.4M
- CVKD 33.7M
- IPO Year
- OPAD N/A
- CVKD 2023
- Fundamental
- Price
- OPAD $0.99
- CVKD $13.60
- Analyst Decision
- OPAD Hold
- CVKD Strong Buy
- Analyst Count
- OPAD 5
- CVKD 1
- Target Price
- OPAD $2.38
- CVKD $32.00
- AVG Volume (30 Days)
- OPAD 36.8K
- CVKD 22.0K
- Earning Date
- OPAD 05-05-2025
- CVKD 05-08-2025
- Dividend Yield
- OPAD N/A
- CVKD N/A
- EPS Growth
- OPAD N/A
- CVKD N/A
- EPS
- OPAD N/A
- CVKD N/A
- Revenue
- OPAD $794,159,000.00
- CVKD N/A
- Revenue This Year
- OPAD N/A
- CVKD N/A
- Revenue Next Year
- OPAD $36.07
- CVKD N/A
- P/E Ratio
- OPAD N/A
- CVKD N/A
- Revenue Growth
- OPAD N/A
- CVKD N/A
- 52 Week Low
- OPAD $0.92
- CVKD $5.70
- 52 Week High
- OPAD $5.35
- CVKD $22.90
- Technical
- Relative Strength Index (RSI)
- OPAD 37.64
- CVKD 37.14
- Support Level
- OPAD $0.95
- CVKD $13.00
- Resistance Level
- OPAD $1.02
- CVKD $15.90
- Average True Range (ATR)
- OPAD 0.07
- CVKD 0.96
- MACD
- OPAD 0.01
- CVKD -0.13
- Stochastic Oscillator
- OPAD 8.00
- CVKD 16.62
About OPAD Offerpad Solutions Inc.
Offerpad Solutions Inc provides a way to buy and sell a home. It uses technology-enabled solutions to remake the home selling and buying experience by offering customers the convenience, control, and certainty to solve their housing needs. It combines fundamental real estate expertise with the data-driven digital Solutions Center platform to efficiently sell and buy their homes online with streamlined access to other services including mortgage, listing, renovation and buyer representation services.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.